Amgen Inc (AMGN)

173.53
1.30 0.73
NASDAQ : Health Care
Prev Close 174.80
Open 174.22
Day Low/High 172.83 / 174.45
52 Wk Low/High 130.09 / 181.81
Volume 1.34M
Avg Volume 2.88M
Exchange NASDAQ
Shares Outstanding 748.36M
Market Cap 131.43B
EPS 9.20
P/E Ratio 15.84
Div & Yield 4.00 (2.30%)

Latest News

Biotech ETFs May Be a Prescription for Investment Success, Especially If Trump Becomes President

Biotech ETFs May Be a Prescription for Investment Success, Especially If Trump Becomes President

Driving sector performance are a recent series of mergers and acquisitions, including Horizon Pharma's purchase of Raptor Pharmaceutical Corp. Then there's the political boost...

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.

FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases

FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases

First Regulatory Approval for Company's Biosimilar Portfolio

Will Amgen (AMGN) Stock Be Helped By FDA Approval of Humira Biosimilar?

Will Amgen (AMGN) Stock Be Helped By FDA Approval of Humira Biosimilar?

The FDA approved Amgen's (AMGN) generic version of AbbVie's (ABBV) Humira drug.

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

Those Wheels Keep Spinning

There are other things to consider besides central banks.

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

First Study to Demonstrate That Lowering LDL Cholesterol With a PCSK9 Inhibitor Impacts Underlying Atherosclerotic Disease on top of Optimized Statin Therapy

Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis

Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis

FRAME Data Simultaneously Published in New England Journal of Medicine and Presented at ASBMR Showed Treatment With Romosozumab Significantly Reduced New Vertebral and Clinical Fractures Through 12 Months

Gilead: Horse of a Different, uh, Color

Gilead: Horse of a Different, uh, Color

The once-mighty biotech has fallen, but entry opportunities will surface.

Spectrum Pharma, FDA and the Buried Truth About a Bladder Cancer Drug Meeting

Spectrum Pharma, FDA and the Buried Truth About a Bladder Cancer Drug Meeting

The FDA told Spectrum not to seek approval for its bladder cancer drug. Spectrum filed anyway but never told investors about the FDA warning.

Amgen Receives Positive CHMP Opinion For Parsabiv™ (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis

Amgen Receives Positive CHMP Opinion For Parsabiv™ (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis

Novel Treatment Administered Intravenously Would put Delivery of Important Therapy in the Hands of the Healthcare Provider

Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine

Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine

Significantly Greater Proportion of Patients on Erenumab Experienced a 50 Percent or More Reduction in Number of Migraine Days Compared to Placebo

Amgen To Webcast Investor Call

Amgen To Webcast Investor Call

Amgen (AMGN) Stock Is Wednesday's 'Chart of the Day'

Amgen (AMGN) Stock Is Wednesday's 'Chart of the Day'

Amgen's (AMGN) last run to highs stalled out, but the stock could still push through the old highs, according to TheStreet's Chris Versace and Bob Lang.

Is Amgen the Cure for the Market Blues?

Is Amgen the Cure for the Market Blues?

The shares have some power and legs to get up and through old highs.

Chart of the Week: Amgen

AMGN has some power and legs to get up and through its old highs.

AbbVie's Battle Royale

AbbVie's Battle Royale

Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?

Big Pharma Spends Millions to Keep Prices High for California Agencies

Big Pharma Spends Millions to Keep Prices High for California Agencies

Drug companies like Merck, Pfizer and Johnson & Johnson are spending big bucks on the opposition of Proposition 61.

5 Healthy Pharma and Biotech Plays

5 Healthy Pharma and Biotech Plays

These stocks look good as seasonal volatility sets in.

Charts Show Something Broke Friday

Charts Show Something Broke Friday

Often, pictures speak louder than words.

Here's When You Should Buy Amgen

Here's When You Should Buy Amgen

Shares of Amgen are under pressure today. Here's how to trade it from here.

Amgen To Highlight 19 Abstracts On Osteoporosis Disease State And Treatment At American Society For Bone And Mineral Research Annual Meeting

Amgen To Highlight 19 Abstracts On Osteoporosis Disease State And Treatment At American Society For Bone And Mineral Research Annual Meeting

Results From Phase 3 FRAME Study of Romosozumab Evaluate Fracture Risk Reduction in Women With Postmenopausal Osteoporosis

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.

Amgen Has Many Ways to Win

Amgen Has Many Ways to Win

Investors have been cautious on Amgen, but the company has a strong pipeline of drugs in development.